Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and ADME of Izencitinib in Healthy Men
NCT03408470Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of izencitinib in ulcerative colitis (UC) and Crohn's disease (2 cohorts), sponsored by Theravance Biopharma, Inc. Primary endpoints: Maximum observed concentration in Plasma up to 15 days, Time to maximum observed concentration in Plasma up to 15 days and 6 more. Started Jan 2018; status: completed.
02
Drugs
izencitinib
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03408470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408470.